What is DAV121?
β-lactam antibiotics constitute the largest and most used class of antibacterial drugs (around 40% of all prescriptions in the community setting and 50% in the hospital). It consists in three families of products, penicillins, cephalosporins and carbapenems, with activity on a broad spectrum of pathogens, and includes some products of last resort. During oral and parenteral treatments, part of the dose reaches the cecum and colon where it disrupts the endogenous microbiota thereby promoting colonization of the gut by potential pathogens and contributing to the selection and expansion of resistant strains. Indeed, the gut is considered as the epicentre of resistance for key resistant species included in the 2017 WHO Global priority list of antibiotic-resistant bacteria, including 3rd generation cephalosporin-resistant and carbapenem-resistant Enterobacteriaceae (priority 1 critical), vancomycin-resistant resistant Enterococcus faecium (priority 2 high), and at least partially carbapenem-resistant A. baumannii and carbapenem-resistant P. aeruginosa (both priority 1 critical).
DAV121 is a novel and innovative colon-delivered β-lactamase enzyme able to hydrolyze β-lactam antibiotic residues in the gut. The DAV121 β-lactamase was developed by site-directed mutagenesis from a naturally-occurring bacterial enzyme. It was optimized to achieve, under human intestinal conditions, effective degradation of all β-lactam antibiotics used in clinical practice, including carbapenems. By preventing β-lactam residues from disrupting the intestinal microbiota, DAV121 aims to prevent dysbiosis and in particular emergence of resistance to carbapenems, clearly helping good antibiotic stewardship.
|Product|| ||Discovery||Preclinical||Phase 1||Phase 2||Phase 3||Market
|DAV121||Preventing Antibiotic Resistance with Carbapenems|| || || || || ||